# A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

Source: https://onco.cc/trials/nct06504147/  
OnCo record `nct06504147` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Radspherin in ovarian cancer, run by Oncoinvent Solutions AS, now recruiting.

## Summary

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery is a phase 2 interventional study registered as NCT06504147 by Oncoinvent Solutions AS, with 114 participants planned, started 2024-06-15 and due to reach its primary completion in 2028-02-29. Interventions recorded: Radspherin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06504147
- Phase: 2
- Setting: A Phase 2, Randomised, Open Label, Multicentre Study of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Primary Advanced High-grade Serous or High-grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient and Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
- Sponsor: Oncoinvent Solutions AS
- Enrolled: 114

## Sources

- ClinicalTrials.gov NCT06504147: https://clinicaltrials.gov/study/NCT06504147

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/nct06504147.json